Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CEROW
Upturn stock ratingUpturn stock rating

CERo Therapeutics Holdings Inc (CEROW)

Upturn stock ratingUpturn stock rating
$0.02
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: CEROW (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit -83.33%
Avg. Invested days 23
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size ETF
Market Capitalization 0 USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta 0.43
52 Weeks Range 0.00 - 0.04
Updated Date 06/13/2025
52 Weeks Range 0.00 - 0.04
Updated Date 06/13/2025
Dividends yield (FY) -
Basic EPS (TTM) -

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -122.86%
Return on Equity (TTM) -

Valuation

Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating 317536
Shares Outstanding -
Shares Floating 317536
Percent Insiders -
Percent Institutions -

ai summary icon Upturn AI SWOT

CERo Therapeutics Holdings Inc

stock logo

Company Overview

overview logo History and Background

CERo Therapeutics Holdings Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer. The company was founded with the goal of harnessing the power of the body's immune system to fight cancer. Specific founding year and early milestones are currently not readily available.

business area logo Core Business Areas

  • Cell Therapy Development: Developing cell-based immunotherapies, primarily focused on CAR-T cell therapies and other engineered cell therapies.
  • Preclinical Research: Conducting preclinical research to identify and validate novel targets for cancer immunotherapy.
  • Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of its lead product candidates in various cancer indications.

leadership logo Leadership and Structure

Information regarding CERo Therapeutics Holdings Inc.'s specific leadership team and organizational structure is currently not readily available.

Top Products and Market Share

overview logo Key Offerings

  • CER-123: A lead CAR-T cell therapy candidate targeting specific tumor antigens. Market share is not available due to its clinical stage. Competitors in CAR-T therapy include Novartis (Kymriah), Gilead Sciences (Yescarta), and Bristol Myers Squibb (Breyanzi).
  • CER-456: Another CAR-T cell therapy candidate targeting specific tumor antigens. Market share is not available due to its clinical stage. Competitors in CAR-T therapy include Novartis (Kymriah), Gilead Sciences (Yescarta), and Bristol Myers Squibb (Breyanzi).

Market Dynamics

industry overview logo Industry Overview

The immunotherapy market is experiencing substantial growth driven by advances in cell therapy, checkpoint inhibitors, and other innovative approaches. The competitive landscape is crowded with both large pharmaceutical companies and smaller biotechnology firms.

Positioning

CERo Therapeutics Holdings Inc. is positioned as an emerging player in the cell therapy space, focusing on developing novel CAR-T cell therapies. Competitive advantages depend on the differentiation and efficacy of their specific CAR-T candidates.

Total Addressable Market (TAM)

The global cell therapy market is projected to reach billions of dollars. CERo Therapeutics Holdings Inc.'s position within this TAM depends on the success of its clinical trials and commercialization efforts, but is currently a small portion.

Upturn SWOT Analysis

Strengths

  • Novel CAR-T cell therapy candidates
  • Focus on specific tumor antigens
  • Potential for improved efficacy and safety compared to existing therapies

Weaknesses

  • Early-stage clinical development
  • Limited financial resources compared to larger pharmaceutical companies
  • High risk of clinical trial failure

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Expansion into new cancer indications
  • Advancements in cell therapy technologies

Threats

  • Competition from established players in the cell therapy market
  • Regulatory hurdles
  • Unfavorable clinical trial results

Competitors and Market Share

competitor logo Key Competitors

  • NVS
  • GILD
  • BMY

Competitive Landscape

CERo Therapeutics Holdings Inc. faces significant competition from established players with greater resources. Its success depends on demonstrating superior efficacy and safety in its clinical trials.

Growth Trajectory and Initiatives

Historical Growth: Historical growth data is limited due to the company's early stage.

Future Projections: Future projections depend heavily on the success of clinical trials and potential partnerships. Analyst estimates are not currently available.

Recent Initiatives: Recent initiatives likely involve advancing its lead CAR-T cell therapy candidates through clinical development.

Summary

CERo Therapeutics Holdings Inc. is a high-risk, high-reward clinical-stage company. Its success hinges on the development of its CAR-T cell therapy candidates. It needs to secure partnerships and financing while navigating a competitive landscape and regulatory hurdles. If its clinical trials have positive results, it is likely to be a good company in the sector, but it is only a small company that is in the clinical phase.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings (when available)
  • Industry Reports
  • Analyst Reports (when available)

Disclaimers:

The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on your own research and due diligence. Market share percentages are approximated.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About CERo Therapeutics Holdings Inc

Exchange NASDAQ
Headquaters South San Francisco, CA, United States
IPO Launch date 2021-11-29
CEO & Chair Mr. Christopher B. Ehrlich M.B.A.
Sector Healthcare
Industry Biotechnology
Full time employees 8
Full time employees 8

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.